The opportunity exists for wholesale investors to register interest in acquiring shares in Orbis Diagnostics.

Orbis Diagnostics’ vision is that each doctor’s office will have an automated and miniaturised laboratory that can undertake a routine panel tests rapidly from a few drops of blood while a patient waits for their appointment.

Orbis has developed the Orbis Arca, which miniaturises the blood testing lab for deployment to points of care. Requiring only a finger-prick of blood and no pipetting, it is designed to be quick, easy, and pain-free for both the patient and the operator without compromising on quantitative accuracy and analytical sensitivity.  

Having completed initial development of its testing platform, which was validated in a clinical study, the company is focusing on producing its range of panels, starting with hepatitis. In the medium term Orbis’ panel range will include liver health, lipid (cholesterol) panels, fertility and inflammatory and metabolic markers.

Five reasons to love Orbis:

• Early traction: Orbis has completed a clinical trial (https://www.medrxiv.org/content/10.1101/2021.11.30.21267102v1) including 100 staff from Air New Zealand that successfully demonstrated the high accuracy of the test and usability of the Arca in a real-world environment. Additionally, Orbis has partnered with IDEMIA (US$2.6B 2020 revenue), a global leader in digital identity solutions, to securely integrate the Orbis’ health data with customer identity.
• Syndicate of value-add investors: Our co-investors in Orbis include a New Zealand venture capital fund, and a European multinational. Having other deep-pocketed investors around the table gives us confidence that we can continue to fund future fundraises together.
• Rapidly growing multi-billion dollar market: The global point of care diagnostics market size is expected to hit around USD 93.21 billion by 2030 and is poised to grow at a CAGR of 11.1% from 2021 to 2030. The growth of the market is driven by a growing and ageing population with increased prevalence of chronic disease, and accelerated by the Covid-19 pandemic’s increasing demand for time-critical healthcare decision making.
• Differentiated proprietary product: Orbis’s multi-patented product offers unique advantages over existing solutions. Orbis’s point-of-care competitors either sacrifice the user experience by requiring a venous blood draw and/or manual pipetting of samples, or sacrifice quantitative accuracy by using lateral flow technology. Orbis’ product is the first fully automated, shrunk-down lab that can maintain high accuracy and speed of serology, antigen and eventually enzymatic and chemistry while offering a finger-prick, easy sampling process. These advantages are achieved through innovations in microfluidics, photonics and robotics and represent a significant barrier to entry for competitors. Orbis’ system also affords tremendous flexibility as the Arca can run a test panel for 1 person within a single test on up to 8 people within 15 minutes.

Motivated shareholder wishes to meet the market – share price represents a 57.6% discount to the last transaction price.

To be put in contact with Pacific Channel for more investment information, click Register Interest.